GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Novo Nordisk, the Danish pharma company behind Ozempic, made a very dumb decision a few years ago that will massively eat ...

A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

“GLP-1 drugs don’t just curb appetite – they dull the desire to drink at a metabolic level. With cravings suppressed and ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Airfares from Europe to the United States have dropped to rates not seen since before the pandemic, as travellers from Western Europe lead a pullback in travel to the U.S. that is expected to continue ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...

SANA changes the conversation. It’s an obesity pill that fights fat, not your body. If it holds up in larger trials, this ...